Echinocandins Flashcards
Echinocandins
Caspofungin
Micafungin
Anidulafungin
Their MOA is distinct
Three drugs have virtually identical spectra
Very well tolerated
Excellent activity against Candida
Lack an oral formulation
Considerably fewer drug interactions than azoles
Safer than polyenes
Great activity against fluconazole resistant yeasts
Echinocandins MOA
Inhibit beta-1,3-D-glucan synthase- the enzyme responsible for production of beta-1,3-D-glucan (a vital component of the cell wall of many fungi)
Only active against fungi that are dependent on this type of glucan
Echinocandins Spectrum
Good C. albicans C. glabrata C. lusitaniae C. parapsilosis C. tropicalis C. krusei Aspergillus species
Moderate
C. parapsilosis
Some dimorphic fungi
Mucorales (in combo with AmphoB)
Poor
Most non-Aspergillus molds
Cryp. neoformans
Echinocandins Adverse Effects
Excellent safety profile
Can cause mild histamine-mediated infusion related reactions (not common and can be ameliorated by slowing the infusion rate)
Hepatotoxicity is also possible with any of these but not common
Echinocandins Important Facts
Differences between agents are minor; mostly PK
Caspofungin and Micafungin eliminated hepatically (noncytochrome P450)
Anidulafungin degrades in plasma; avoids hepatic metabolism (but not completely devoid of hepatotoxicity)
Have excellent cidal activity against Candida; against Aspergillus activity is neither classically cidal or static (cause aberrant nonfunctional hyphae to be formed by the actively growing mold)
Only modestly active against molds; substantially enhance effects of other antifungals against these pathogens; trend toward reduced mortality among combo therapy (p value = 0.07 in this study; there is low toxicity with echinocandins so clinicians still advocate for combo therapy)
May also enhance effects of LAmB against Mucorales (based on in vitro and limited clinical data)
Drug interactions are minor
Take caution:
Caspofungin (with cyclosporine)
Micafungin (with Sirolimus)
Are not cheap and are IV only
After beginning empiric therapy with echinocandin, consider switching to fluconazole of susceptible strain and no contraindications to fluconazole
Echinocandins Good For
Drugs of choice for invasive candidiasis (especially in patients who are clinically unstable and at risk for azole resistant species)
Useful in invasive aspergillosis (do not have as much supporting data as voriconazole and the polyenes)
All used for esophageal candidiasis
Some used for prophylaxis or empiric therapy of fungal infections in neutropenic patients
To increase likelihood of cure, will add echinocandin to:
Voriconazole (for Aspergillus)
AmphoB (for Mucorales)